PD79 Cost Heterogeneity Across Health Sectors And Its Impact On Coverage Decisions for Metastatic Prostate Cancer Treatment In Argentina

Introduction Argentina’s healthcare system is fragmented, comprising public, private, and social security sectors. The guidance for incorporating a new health technology into the healthcare system suggests a single threshold value (0.016% of total health expenditure). This study analyzed the influence of cost heterogeneity on budget impact using the reimbursement of talazoparib for the treatment of metastatic prostate cancer as an example. Methods A budget impact analysis (BIA) was adapted for the National Institute of Social Services for Retirees and Pensioners and SURGE (union social security sector) perspectives. To be able to estimate the impact of medical costs, other parameters such as population and market share were fixed. Drug costs were estimated using reimbursement values, while the costs of healthcare resources and management of adverse events were obtained from the 3Eff SA cost database (3val), which is based on tariffs of institutions within the subsectors of the Argentine healthcare system. Results For direct medical resources (medication, medical consultations, laboratory tests, etc.) associated with metastatic prostate cancer treatment, cost heterogeneity across health sectors was 79 percent. The lowest variability was observed in laboratory tests (18%), while the highest was in medical consultations (310%). The cost of managing adverse events varied by 38 percent across sectors, with the highest variability in managing fatigue (118%) and the lowest in thrombocytopenia (2.4%). As a result, the average annual budget impact varied across sectors by just over 15 percent. Conclusions Our results showed a significant heterogeneity in costs among Argentina’s healthcare subsectors. This heterogeneity might lead to different reimbursement decisions based on the BIA results. Variability in costs underscores the need for sector-specific guidelines or thresholds for reimbursement decisions to ensure equitable and efficient resource allocation.

Authors

Publication Details

Journal
International Journal of Technology Assessment in Health Care
Published
2025-12-01
DOI
https://doi.org/10.1017/s0266462325102067
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PD79 Cost Heterogeneity Across Health Sectors And Its Impact On Coverage Decisions for Metastatic Prostate Cancer Treatment In Argentina

Gonzalo Guiñazú, Mariana Glancszpigel, Juan De Bonis, Silvana De Cicco et al.
International Journal of Technology Assessment in Health Care
Health Systems, Economic Evaluations, Quality of Life
article

PD79 Cost Heterogeneity Across Health Sectors And Its Impact On Coverage Decisions for Metastatic Prostate Cancer Treatment In Argentina

Gonzalo Guiñazú, Mariana Glancszpigel, Juan De Bonis, Silvana De Cicco, Lucila Rey-Ares, Jorge Elgart
article en

Abstract

Introduction Argentina’s healthcare system is fragmented, comprising public, private, and social security sectors. The guidance for incorporating a new health technology into the healthcare system suggests a single threshold value (0.016% of total health expenditure). This study analyzed the influence of cost heterogeneity on budget impact using the reimbursement of talazoparib for the treatment of metastatic prostate cancer as an example. Methods A budget impact analysis (BIA) was adapted for the National Institute of Social Services for Retirees and Pensioners and SURGE (union social security sector) perspectives. To be able to estimate the impact of medical costs, other parameters such as population and market share were fixed. Drug costs were estimated using reimbursement values, while the costs of healthcare resources and management of adverse events were obtained from the 3Eff SA cost database (3val), which is based on tariffs of institutions within the subsectors of the Argentine healthcare system. Results For direct medical resources (medication, medical consultations, laboratory tests, etc.) associated with metastatic prostate cancer treatment, cost heterogeneity across health sectors was 79 percent. The lowest variability was observed in laboratory tests (18%), while the highest was in medical consultations (310%). The cost of managing adverse events varied by 38 percent across sectors, with the highest variability in managing fatigue (118%) and the lowest in thrombocytopenia (2.4%). As a result, the average annual budget impact varied across sectors by just over 15 percent. Conclusions Our results showed a significant heterogeneity in costs among Argentina’s healthcare subsectors. This heterogeneity might lead to different reimbursement decisions based on the BIA results. Variability in costs underscores the need for sector-specific guidelines or thresholds for reimbursement decisions to ensure equitable and efficient resource allocation.

International Journal of Technology Assessment in Health CareVol. 41(S1)
Openalex Percentile: Top 21%
Health Systems, Economic Evaluations, Quality of Life
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

PD79 Cost Heterogeneity Across Health Sectors And Its Impact On Coverage Decisions for Metastatic Prostate Cancer Treatment In Argentina — Gonzalo Guiñazú, Mariana Glancszpigel, et al. · International Journal of Technology Assessment in Health Care (2025) | TGRS Research Map | TGRS